Comparative Pharmacology
Head-to-head clinical analysis: MOMETASONE FUROATE versus PULMICORT RESPULES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOMETASONE FUROATE versus PULMICORT RESPULES.
MOMETASONE FUROATE vs PULMICORT RESPULES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, reduced arachidonic acid release, and decreased synthesis of prostaglandins and leukotrienes. It also suppresses cytokines, chemokines, and adhesion molecules involved in inflammation.
Glucocorticoid receptor agonist; anti-inflammatory; decreases cytokine production, inhibits inflammatory cell migration, and reduces airway hyperresponsiveness.
Inhaled: 110-880 mcg twice daily; Intranasal: 2 sprays (50 mcg/spray) per nostril once daily; Topical: Apply thin film to affected area once daily.
0.5 mg to 1 mg twice daily via nebulization; for maintenance or as replacement therapy, initiate at 0.25 mg twice daily and titrate to clinical response.
None Documented
None Documented
The terminal elimination half-life is approximately 5.8 hours (range 4.5–7.5 hours) following intravenous administration; after intranasal or inhalation use, the effective half-life supporting once-daily dosing is derived from receptor binding and local tissue retention.
Terminal half-life approximately 2-3 hours in children and adults; slightly prolonged in hepatic impairment. Clinical context: supports twice-daily dosing in asthma.
Mometasone furoate is extensively metabolized in the liver; less than 1% of the dose is excreted unchanged in urine. The metabolites are primarily excreted in feces (~74%) via biliary elimination, with renal excretion accounting for approximately 8–10%.
Renal: negligible (<5% as unchanged drug). Biliary/fecal: major route, approximately 60-70% as metabolites. Total clearance: 0.5-1.0 L/h.
Category A/B
Category C
Topical / Inhaled Corticosteroid
Inhaled Corticosteroid